Validation Summary Report
Frequently Asked Questions (VSR)

A Validation Summary Report is the controlled closeout document that evaluates completed validation evidence and records whether a system is acceptable for its intended GxP use.

A strong VSR identifies the exact system and version, confirms the approved scope, summarises the risk-based assurance activities, reconciles deviations and unresolved issues, confirms traceability, states any accepted residual risk, and records the final approval or release decision.

It should synthesise the evidence rather than reproduce every protocol or test result. A reviewer should be able to understand why the conclusion is justified and then follow document references to the underlying records.

The exact title "Validation Summary Report" is not universally mandated, but documented validation results and lifecycle reports are expected.

EU GMP Annex 11 requires validation documentation and reports to cover relevant lifecycle steps and to include applicable change-control records and reports of deviations. FDA software-validation guidance, within its medical-device scope, identifies a validation summary as part of the documentation that objectively confirms software is validated for its intended use.

For that reason, many regulated organisations use a VSR, Final Validation Report, Validation Report or equivalent closeout record. The important point is the evidence and authorised conclusion, not the document title alone.

Every validation effort needs documented closure, but the closure record does not always need to be a standalone document called a VSR.

A major system implementation will usually justify a dedicated VSR. A small, low-risk change may be closed through a validation section in the approved change record or a concise change-validation report, provided the record still shows intended use, risk, evidence performed, issues found, final disposition and approval.

Your validation procedure should define when a standalone VSR is required and when another controlled closeout format is acceptable.

In some quality systems the terms are synonyms; in others, "validation report" can describe a phase or change while the VSR closes the complete validation package.

Avoid relying on terminology that has not been defined. Your SOP, Validation Plan and document templates should state whether the terms are interchangeable and which record authorises final closure.

Consistency is more important than the label: document IDs, scope, version, approval state and cross-references should make the document's role unmistakable.

The Validation Plan is prospective—it defines what will be done—while the VSR is retrospective and evaluative—it records what was done and whether the evidence supports release.

The VSR should explicitly identify material departures from the approved plan and explain their impact. Silent differences between the plan and final report create avoidable inspection questions.

• Validation Plan: scope, roles, lifecycle approach, deliverables, methods, acceptance criteria and deviation strategy.
• Validation Summary Report: actual activities, approved evidence, departures from the plan, test or assurance outcomes, deviations, residual risk and final conclusion.

IQ, OQ and PQ reports contain detailed phase-level evidence; the VSR integrates the conclusions across the entire validation effort.

The VSR should reference approved phase reports, summarise their outcomes and reconcile their deviations without copying every test step. It should also include evidence outside the IQ/OQ/PQ structure, such as supplier assessment, configuration verification, data migration, security, user acceptance testing or unscripted assurance activities.

Under a CSA-style approach, the evidence may not be organised into traditional IQ/OQ/PQ phases at all. The VSR can still summarise the risk-based activities and explain why they are sufficient for the intended use.

An inspection-ready VSR should make the final decision auditable from one document while linking clearly to the underlying evidence.

The headings may differ by organisation. What matters is that the report contains enough objective information to support the conclusion and that every referenced record can be located.

• Document control, author, reviewers, approvers and revision history.
• System identity, version, intended use, business process and GxP impact.
• Approved scope, interfaces, sites, data and explicit exclusions.
• Validation strategy and the risk assessments used to scale activities.
• Deliverable register with document IDs, versions and approval status.
• Summary of testing or assurance activities and their results.
• Deviation, failure, issue and CAPA summary with final disposition.
• Requirements-traceability status, including any justified exceptions.
• Residual-risk assessment, outstanding actions and release conditions.
• Conclusion, release or non-release decision, effective date and approvals.

Write the VSR as a controlled evidence reconciliation: establish the approved boundary, assemble the final records, resolve discrepancies, assess residual risk and only then write the conclusion.

Start the document shell during planning, but do not pre-decide the outcome. The final narrative and release decision must follow the approved evidence rather than the project schedule.

• Confirm the system identity, version, environment, intended use and approved validation scope.
• Reconcile the Validation Plan against the activities and deliverables actually completed.
• Compile approved document references, assurance results and traceability status from controlled sources.
• Reconcile every failure, deviation, change and open action with its impact assessment and disposition.
• Assess whether the combined evidence satisfies acceptance criteria and whether residual risk is acceptable.
• Draft an evidence-bounded conclusion, release conditions, effective date and post-release responsibilities.
• Route the report through the review and approval roles defined by the organisation's quality system.

The executive summary should identify the system and intended use, state the validation scope and outcome, disclose material unresolved items, and give the release decision.

A useful summary is normally a few concise paragraphs, not a marketing description. It should tell a quality reviewer what was validated, which version and environment were assessed, whether the approved acceptance criteria were met, whether any residual risk remains, and where the detailed evidence is referenced.

Avoid unsupported phrases such as "fully compliant" or "all risks eliminated." State the evidence-based conclusion and its boundaries.

The VSR should make an explicit traceability statement and reference the approved Requirements Traceability Matrix by document ID and version.

State whether all in-scope requirements are linked to suitable verification or assurance evidence and whether each result has a final disposition. Include totals or exception counts when they help the reviewer reconcile the report with the RTM.

Any untested, deferred, retired or not-applicable requirement should be listed or referenced with a documented rationale and approval. A generic sentence saying "traceability is complete" is weak if the underlying RTM still contains blanks or unresolved exceptions.

Every material exclusion should identify what was excluded, why it was excluded, the risk rationale, any compensating control and who approved the decision.

The final scope should reconcile with the Validation Plan, impact assessment and risk assessment. If the project scope changed, the VSR should identify the approved change rather than silently presenting a different scope.

For interfaces, reports, migrated data or optional modules, define the exact boundary. Broad wording such as "non-GxP functions excluded" is not sufficient unless the excluded functions are identifiable.

A CSA-aligned VSR should summarise objective evidence in proportion to risk instead of forcing every activity into a document-heavy IQ/OQ/PQ format.

For each material function or assurance area, identify the intended use, risk-based analysis, assurance method, result, issues found and final acceptability conclusion. Record who performed the work, when it was performed and the review or approval applied when appropriate.

The final FDA CSA guidance is scoped to medical-device production and quality-management-system software. Its evidence principles may be useful elsewhere, but the page should preserve that regulatory boundary.

The VSR should preserve the original failure and show the full path to final disposition; it should never report only the later passing retest.

Reference the failed test or assurance activity, associated deviation, investigation or root cause, impact assessment, correction or control, retest evidence and closure approval. The summary counts should reconcile with the detailed protocol and deviation log.

A retest demonstrates the result after correction; it does not erase the original event. The report should explain why the combined evidence supports—or does not support—the final conclusion.

The conclusion should identify the exact system, version and intended use; state whether the approved evidence supports acceptability; disclose residual risk; and record the authorised release decision.

It should also identify any conditions, post-release actions or restrictions and the date on which the decision becomes effective. Avoid a vague statement such as "the system is validated" without defining the validated configuration and intended use.

Where the organisation uses a separate System Release Certificate, the VSR can provide the evidence-based conclusion and the certificate can record the formal operational authorisation.

A useful VSR template should prompt for the evidence needed to support a release decision, not provide generic wording that can be approved without project-specific facts.

Treat an example as a structural reference only. Copying another project's conclusion, test totals, risk language or regulatory scope can create a misleading record.

• Document control, revision history and defined signature meanings.
• System name, version, environment, owner, intended use and GxP impact.
• Approved scope, exclusions, interfaces, sites and data boundaries.
• Validation strategy, risk basis and a register of approved deliverables.
• Assurance-result totals that preserve failures, retests and final dispositions.
• Deviation and open-action reconciliation, including residual-risk decisions.
• Traceability status and references to the approved RTM or equivalent evidence map.
• A bounded conclusion, release conditions, effective date and lifecycle handover actions.

There is no single universally mandated VSR format or page count; the report should be proportionate to the system, risk, scope and evidence package.

A short report can be adequate for a narrow, low-risk change if it clearly supports the decision. A complex enterprise implementation may require more detail, appendices and cross-reference tables. Length alone is not evidence of quality.

Use a controlled template that enforces the core decision fields while allowing risk-based tailoring. Do not create empty sections merely to satisfy a generic template.

Routine GxP use should begin only after the authorised release decision required by the organisation's quality system; that decision may be recorded in the VSR or in a separate controlled release record.

The VSR title itself is not the controlling factor. The controlling factor is whether the required validation evidence has been evaluated and an authorised person or function has formally approved the system for the defined intended use.

Emergency, pilot or conditional use should follow an approved procedure with documented risk controls and restrictions. An informal agreement to "finish the paperwork later" is not a substitute for controlled authorisation.

An open item can be accepted only when its impact is understood, the residual risk is acceptable, controls and ownership are documented, and the organisation's procedure permits approval or conditional release.

An unresolved issue should block release when it prevents demonstration of intended use, leaves a critical requirement unverified, compromises data integrity or product quality, creates unacceptable patient risk, or means an approved acceptance criterion has not been met.

Low-risk administrative or non-release-blocking items may sometimes remain open, but the VSR should identify the item, rationale, interim control, responsible owner, due date and escalation path. Do not rely on severity labels alone.

Use the approved deviation-classification procedure; FDA and EU GMP do not provide one universal VSR definition for "Critical," "Major" and "Minor."

Classification should reflect the potential effect on intended use, patient safety, product quality, data integrity, regulatory compliance and the reliability of the validation conclusion. Include a documented rationale and final disposition rather than applying a label by habit.

The VSR summary should use the same classification and status as the controlled deviation system. Differences in counts or severity between the VSR and deviation log should be reconciled before approval.

Conditional release is a controlled, temporary authorisation to use a system within defined limits while specified low-risk items remain outstanding; it is not an automatic regulatory entitlement.

Only use conditional release when the organisation's quality system explicitly supports it. The final closure record should confirm that all conditions were resolved or formally re-evaluated.

• The exact outstanding items and their assessed impact.
• Why the residual risk is acceptable for the proposed use.
• Interim controls, restrictions or monitoring requirements.
• Named owners, committed completion dates and escalation rules.
• The approval authority and the event that ends or renews the condition.

An issue is release-blocking when the available evidence cannot support safe, reliable and compliant use of the affected function within the approved intended use.

• A critical requirement or control has not been verified.
• The system cannot consistently perform an intended GxP function.
• The issue creates unacceptable risk to patient safety, product quality or data integrity.
• A required security, audit-trail, record or electronic-signature control is ineffective.
• The root cause or scope of impact is unknown and cannot be bounded.
• An approved release acceptance criterion remains unmet.

The VSR evaluates and summarises the evidence; a System Release Certificate records the formal authorisation to place the defined system or configuration into operational use.

Some organisations combine both functions in one approved VSR. Others separate them because the people who assess validation evidence are not the same people who authorise production use, site deployment or business cutover.

Where separate records are used, each should reference the other by document ID and version so the decision trail is unambiguous.

The organisation's SOP should define the roles; regulations expect clear responsibilities but do not prescribe one universal VSR signature list.

A typical model assigns preparation to the validation lead or project team, technical and business review to relevant subject-matter experts and the system or process owner, and independent quality review or approval to Quality Assurance where required by the pharmaceutical quality system.

Each signature should have a defined meaning—such as authorship, technical review, business ownership, quality approval or release authorisation. Do not add signatures that have no documented responsibility.

Yes, a qualified vendor or consultant may prepare the document, but the regulated organisation retains responsibility for its intended use, evidence assessment and approval.

The regulated user should verify that supplier evidence is applicable to its configured system, operating environment and business process. Vendor authorship does not transfer accountability for scope, acceptance criteria, deviations, residual risk or release.

Responsibilities should be defined in contracts, quality agreements or project governance records, and the final VSR should be reviewed through the organisation's document-control process.

Create the VSR shell during planning, populate factual sections as evidence is approved, and finalise the conclusion only after the planned activities and issue assessments are complete.

Progressive drafting helps teams detect missing document IDs, inconsistent test counts, unresolved traceability and unapproved deviations before the release meeting. It also reduces the risk of reconstructing the project from memory at the end.

Do not pre-write a passing conclusion. The final decision must follow the evidence, including any departures from the original plan.

Reviewers test the internal consistency of the VSR and trace selected statements back to controlled evidence; polished prose cannot compensate for mismatched records.

• The system, version, environment and intended use match the approved scope.
• Referenced deliverables exist, have the stated versions and were approved in the correct sequence.
• Test and assurance totals reconcile with protocols, digital records and phase reports.
• Failures, deviations and open actions reconcile with the controlled issue system.
• Requirements and critical controls can be traced to suitable evidence.
• Approvals occur after the activities they are intended to accept.
• The final conclusion is limited to what the evidence actually demonstrates.

A VSR should be a controlled record with an audit trail or revision history; however, the approved baseline report is not automatically reopened for every later change.

Post-release changes are normally assessed and closed through change control, with change-specific validation or assurance records. The original VSR remains part of the baseline history unless an error, omitted evidence or the organisation's procedure requires a formal revision.

Periodic evaluation and the system validation file should provide the current validation status by linking the baseline VSR, subsequent changes, incidents, upgrades and revalidation records.

A cloud or SaaS VSR has the same closeout objective but should explain how supplier evidence, service controls, configuration, interfaces and ongoing vendor releases were assessed for the customer's intended use.

Summarise supplier qualification, service or quality agreements, tenant configuration, data migration, security and access controls, backup and recovery responsibilities, release-management arrangements and any customer-performed assurance activities.

Do not treat a vendor certificate or generic test pack as automatic proof that the customer's configured process is fit for its intended GxP use.

A digital validation platform can reduce manual reconciliation by generating the VSR summary from controlled requirements, test, deviation, approval and traceability records.

The strongest benefit is data consistency: document versions, test counts, failures, approvals and RTM status can be drawn from the same source records rather than copied into separate spreadsheets and reports.

Automation should not make the release decision by itself. Qualified people must still assess scope, evidence quality, unresolved risk and the acceptability conclusion under the organisation's quality system.

The most serious VSR problems are contradictions between the report and the underlying evidence, not formatting imperfections.

• Calling the system "validated" without defining version, environment or intended use.
• Claiming all tests passed while the protocols contain failures or unresolved exceptions.
• Using deviation counts or classifications that do not match the controlled deviation log.
• Stating traceability is complete while the RTM contains blanks, duplicates or unapproved exclusions.
• Omitting material departures from the Validation Plan or approved scope.
• Using regulatory citations outside their actual product or jurisdictional scope.
• Approving the VSR before referenced activities or reports are approved.
• Treating a vendor package as a substitute for customer intended-use assessment.
• Using absolute claims such as "zero risk" or "fully compliant" without defined evidence.